SMO Medical Technologies experience
SMO Medical Technologies works with international and local protocols across a broad range of therapeutic areas.
Our core expertise includes patient recruitment and enrollment, Research Site activation, protocol-based patient management, monitoring support and data-quality control.
Leading therapeutic areas
SMO Medical Technologies has a proven track record of recruitment-speed leadership across multiple therapeutic areas.
Non-small cell lung cancer
Vaccination
Endometriosis
Candidiasis
Hemorrhoidal disease
Asthma
Erectile dysfunction
Trauma
Active experience across 40+ therapeutic areas
SMO Medical Technologies has established recruitment leadership across several therapeutic areas, including non-small cell lung cancer, vaccination, endometriosis, candidiasis, hemorrhoidal disease, asthma, erectile dysfunction, and trauma. These results stem from a combination of proprietary patient databases, experienced investigator teams, established referral networks, and centralized management of the research site network.
Study types
Phase I–III studies
Support for early- and late-stage clinical trials: from Research Site assessment and team preparation to patient recruitment, visits, monitoring and documentation.
Phase IV and post-marketing studies
Work with observational and post-registration protocols where patient access, follow-up organization and long-term retention are essential.
Bioequivalence studies
Fast volunteer recruitment, standardized hospitalization conditions, documentation preparation, procedure management and visit control.
Specialized studies
Drug interaction studies, medical device studies, clamp studies and other protocols with specific operational requirements.
Bioequivalence studies
SMO Medical Technologies provides the full operational cycle for bioequivalence studies: feasibility assessment, volunteer recruitment and screening, hospitalization, procedure organization, documentation preparation and monitoring support.
Cases
Expanding recruitment geography
Challenge: limited patient availability in central clinics slowed down study progress.
Result: patient enrollment reached 108% of the planned target.
To overcome recruitment limitations, Medical Technologies expanded the recruitment geography by involving regional clinics and organizing protocol-specific training for their staff.
This approach helped increase patient access, maintain study progress and complete enrollment at 108% of the planned target.
Clinical trials during COVID-19
Challenge: lockdowns and restrictions created a risk of stopping ongoing clinical trials.
Result: study continuity was maintained, and commitments to Sponsors were fulfilled.
During the COVID-19 pandemic, Medical Technologies adapted study processes to rapidly changing conditions. The team implemented remote monitoring, telemedicine elements and strengthened biosafety measures to protect participants and Research Site staff.
As a result, ongoing clinical trials continued without interruption, and obligations to Sponsors were successfully met.
International Research Site launch in Uzbekistan
Challenge: expansion into Central Asia required the launch of a new Research Site and alignment with local regulatory processes.
Result: a new Research Site was successfully launched, expanding recruitment geography and strengthening the company’s international presence.
Medical Technologies provided operational and regulatory support for the launch of a new Research Site in Uzbekistan. The team organized staff training, supported regulatory procedures and helped build local clinical trial capacity.
The project expanded access to new patient populations and strengthened Medical Technologies’ ability to support international clinical trials in Central Asia.